The prognosis of multiple myeloma on current chemotherapy has not improved over the last 20 years;Le pronostic du myelome traite par chimiotherapie conventionnelle ne s'est pas ameliore en 20 ans

Revue de Medecine Interne

Volumn 17, Issue 11, 1996, Pages 895-900

  Dubost, J J ^a   Ristori, J M ^a   Soubrier, M ^a   Zbadi, K ^a   Bussiere J L ^a   Sauvezie, B ^a  

^a SERVICE DE RHUMATOLOGIE   (France)

Author keywords

myeloma; prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; MELPHALAN; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PROGNOSIS; AGED; HOSPITALIZATION; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; STATISTICAL MODEL;

AGED; HOSPITALIZATION; HUMANS; LINEAR MODELS; MIDDLE AGED; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS;

EID: 0030332036     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/0248-8663(96)88119-7     Document Type: Article

References (20)

1. 1 Osgood ED. The survival time of patients with plasmocytic myeloma. Cancer Chemotherap Rep 1960;9:1-10
2. 2 Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984;310:1353-6
3. 3 Durie BGM, Dalton WS. Reversal of drug-resistance in multiple myeloma with verapamil. Br J Haematol 1988;68:203-6
4. 4 Sonneveld P, Durie BGM, Lokhorst HM et al. Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 1992;340:355-9
5. 5 Mandelli F, Avvisati G, Amarodi S et al. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 1990;322:1430-4
6. 6 Dimopoulos MA, Moulopoulos A, Smith T, Delasalle KB, Alexanian R. Risk of disease progression in asymptomatic multiple myeloma. Am J Med 1993;94:57-60
7. 7 Durie BGM, Salmon SE. Clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, responses to treatment and survival. Cancer 1975;36:842-54
8. 8 Salmon SE, Wampler SB. Multiple myeloma: quantitative staging and assessment of response with a programmable pocket calculation. Blood 1977;49:379-89
9. 9 Bergsagel DE. Is aggressive chemotherapy more effective in the treatment of plasma cell myeloma? Eur J Cancer Clin Oncol 1989;25:159-61
10. 10 Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med 1994;330:484-9
11. 11 Medical Research Council's Working Party on Leukemia in Adults. Report on the second myelomatosis trial after five years of follow-up. Br J Cancer 1980;42:813-22
12. 12 Medical Research Council Working Party on Leukaemia in Adults. Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Br J Cancer 1985;52:153-8
13. 13 MacLennan ICM, Chapman C, Dunn J, Kelly K. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. Lancet 1992;339:200-5
14. 14 Pavlovsky S, Corrado C, Santarelli MT et al. An update ot two randomized trials in previously untreated multiple myeloma comparing melphalan and prednisone versus three and five-drug combinations: an argentine group for the treatment of acute leukemia study. J Clin Oncol 1988;6:769-75
15. 15 Levi F, Randimbison L, Te VC, Franceschi S, La Vecchia C. Trends in cancer survival in Vaud, Switzerland. Eur J Cancer 1992;28A:1490-5
16. 16 Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992;10:334-42
17. 17 Gore ME, Viner C, Meldrum M et al. Intensive treatment of multiple myeloma and criteria for complete remission. Lancet 1989;ii:879-81
18. 18 Attal M, Huguet F, Schlaifer D et al. Intensive combined therapy for previously untreated aggressive myeloma. Blood 1992;79:1130-6
19. 19 Buzaid AC, Durie BGM. Management of refractory myeloma: a review. J Clin Oncol 1988;6:889-905
20. 20 Berenson JR, Lichtenstein A, Porter L et al. Efficacity of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996;334:488-93